Tissue Engineering Market: Including Top Companies Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences

Various diseases, injury, and trauma can lead to degeneration and damage of tissues in the human body, which necessitates treatments to enable repair, replacement or regeneration of damaged tissue. The treatment normally focuses on transplanting tissue from one site to another in the same patient (an autograft) or from one individual to another (a transplant or allograft). Tissue engineering is an inter-disciplinarily research area, which has wider applications in repair of organs, regeneration, and tissue transplantation. The technology uses synthetic or naturally derived, engineered biomaterials to replace defective or damaged tissues, such as bone, skin, and organs.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2217

Key manufacturers in the tissue engineering market are focused on mergers and acquisitions, and partnerships with smaller companies. For instance, in 2017, FUJIFILM Corporation invested US$ 3.7 million in the regenerative medicine venture company NC Medical Research, Inc. with NC Medical granting Fujifilm a stock allocation. Rapid advances in stem cell research with a focus on therapeutic potential for regenerative medicine and other biomedical applications are expected to drive market growth. In combination with tissue engineering, stem cells exhibit growth opportunities in further advancing modern medicine. Although much progress has been made in the field of tissue engineering, further research regarding organ and tissue replacement is necessary. The optimal cell source, scaffold design, and in vitro bioreactors, the use and development of microfabrication technology to create vascularized tissues and organs are still being investigated.

Scientific advancements in the fields of cell and molecular biology, genetics, biochemistry, biomedical engineering and materials science have opened new growth opportunities in the field of tissue engineering. Rising need for effective regenerative treatments due to the rapidly aging population coupled with increasing population suffering from diseases such as cancer, diabetes, and obesity and growth in burn and trauma cases are expected to drive the tissue engineering market growth during the forecast period. According to the World Health Organization (WHO), global diabetic population is expected to reach 336 million by 2030, from 270 million in 2015.

However, tissue engineering processes used for development of complex tissues or organs, such as heart, is facing challenges such as dearth of cell sources, biomaterials, vascularization of engineered tissues, and design of drug delivery systems. Moreover, harvesting autografts is painful, expensive, constrained by anatomical limitations and donor-site morbidity due to hematoma and infection, which is hindering growth of the market.

Key players operating in the global tissue engineering market include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.

Get Request For Report Sample @ www.coherentmarketinsights.com/insight/request-sample/2217

Detailed Segmentation:

Global Tissue Engineering Market, By Material Type:
Synthetic
Biological
Others
Global Tissue Engineering Market, By Application:
Dermal
Orthopedic
Dental
Neurology
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,
#3200
Seattle, WA 98154

This release was published on openPR.